Skip to playerSkip to main content
Benzinga
  • 7 hours ago
Regeneron agreed to lower U.S. drug prices under Trump's "most favored nation" effort and will offer its hearing-loss gene therapy Otarmeni for free to eligible U.S. patients following FDA approval. The deal includes a three-year exemption from pharmaceutical tariffs of up to 100%. Otarmeni restored hearing in a small number of deaf children targeting an ultra-rare genetic condition. Piper Sandler estimated peak sales of $130M.
Transcript
00:00It's Benzinga bringing Wall Street to Main Street.
00:03Regeneron agreed Thursday to lower U.S. drug prices for some Americans under a deal with Trump,
00:07according to CNBC. The company will also offer its hearing loss gene therapy for free
00:12to eligible U.S. patients after the Food and Drug Administration approved the treatment
00:16earlier Thursday. The agreement is part of Trump's most favored nation effort to tie U.S. drug
00:23prices to the lowest levels in other developed nations. The deal includes a three-year exemption
00:28from tariffs, including planned levies of up to 100% on some pharmaceutical products.
00:33The gene therapy, Odar Meany, restored hearing in a small number of deaf children and targets
00:39an ultra-rare genetic condition. Piper Sandler estimated peak sales of $130 million.
00:45For all things money, visit Benzinga.com.
Comments